Roche scores first, with FDA approval of Ocrevus Zunovo for MS

The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche (ROG: SIX).

According to the company, Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.

Until the FDA approval of Ocrevus (ocrelizumab), there had been no FDA-approved treatments for PPMS and Ocrevus and Ocrevus Zunovo are still the only approved treatments for PPMS.